Tumour-associated macrophages are an essential component of the tumour
microenvironment and have a role in the orchestration of angiogenesis, extracellular matrix …

In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune
responses of the body. It has become another important modality of anti-tumor therapy with …

The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …

The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1)
blockade in cancer patients, but the mechanisms underlying their immunosuppressive …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Tumor-associated macrophages (TAMs) represent one of the main tumor-infiltrating immune
cell types and are generally categorized into either of two functionally contrasting subtypes …

Single-cell RNA sequencing (scRNA-seq) is a powerful tool for defining cellular diversity in
tumors, but its application toward dissecting mechanisms underlying immune-modulating …